CN112020366A - Pharmaceutical composition containing dipeptide - Google Patents
Pharmaceutical composition containing dipeptide Download PDFInfo
- Publication number
- CN112020366A CN112020366A CN201980028106.3A CN201980028106A CN112020366A CN 112020366 A CN112020366 A CN 112020366A CN 201980028106 A CN201980028106 A CN 201980028106A CN 112020366 A CN112020366 A CN 112020366A
- Authority
- CN
- China
- Prior art keywords
- asp
- pro
- val
- leu
- ile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010016626 Dipeptides Proteins 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 13
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 239000004480 active ingredient Substances 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 230000017306 interleukin-6 production Effects 0.000 claims description 11
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 230000016396 cytokine production Effects 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000018276 interleukin-1 production Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 102000000589 Interleukin-1 Human genes 0.000 description 10
- 108010002352 Interleukin-1 Proteins 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000000413 hydrolysate Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- -1 alkali metal salts Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- ZVDPYSVOZFINEE-BQBZGAKWSA-N alpha-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O ZVDPYSVOZFINEE-BQBZGAKWSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- BSWHERGFUNMWGS-UHFFFAOYSA-N Asp-Ile Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CC(O)=O BSWHERGFUNMWGS-UHFFFAOYSA-N 0.000 description 3
- CPMKYMGGYUFOHS-FSPLSTOPSA-N Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O CPMKYMGGYUFOHS-FSPLSTOPSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000019459 Cynara cardunculus Species 0.000 description 2
- 235000019106 Cynara scolymus Nutrition 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 235000016520 artichoke thistle Nutrition 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012607 strong cation exchange resin Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PHJDCONJXLIIPW-MRVPVSSYSA-N (2r)-4-[(2-methylpropan-2-yl)oxy]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)NC(=O)OC(C)(C)C PHJDCONJXLIIPW-MRVPVSSYSA-N 0.000 description 1
- PHJDCONJXLIIPW-QMMMGPOBSA-N (2s)-4-[(2-methylpropan-2-yl)oxy]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C PHJDCONJXLIIPW-QMMMGPOBSA-N 0.000 description 1
- RAUQRYTYJIYLTF-MRVPVSSYSA-N (3r)-4-[(2-methylpropan-2-yl)oxy]-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](CC(O)=O)C(=O)OC(C)(C)C RAUQRYTYJIYLTF-MRVPVSSYSA-N 0.000 description 1
- RAUQRYTYJIYLTF-QMMMGPOBSA-N (3s)-4-[(2-methylpropan-2-yl)oxy]-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(O)=O)C(=O)OC(C)(C)C RAUQRYTYJIYLTF-QMMMGPOBSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000248539 Asparagus cochinchinensis Species 0.000 description 1
- 235000009292 Asparagus cochinchinensis Nutrition 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- IWXAZSAGYJHXPX-BCEWYCLDSA-N Bisbentiamine Chemical compound C=1C=CC=CC=1C(=O)OCC/C(SS\C(CCOC(=O)C=1C=CC=CC=1)=C(/C)N(CC=1C(=NC(C)=NC=1)N)C=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N IWXAZSAGYJHXPX-BCEWYCLDSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000219992 Cuphea Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 241000965481 Darksidea alpha Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ILKBHIBYKSHTKQ-UHFFFAOYSA-N Diisopropylamine dichloroacetate Chemical compound OC(=O)C(Cl)Cl.CC(C)NC(C)C ILKBHIBYKSHTKQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 241001113425 Iridaceae Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001149162 Mallotus japonicus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 241000555028 Sternidius alpha Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950009892 bisbentiamine Drugs 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 229940084113 diisopropylamine dichloroacetate Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 description 1
- GFEGEDUIIYDMOX-BMJUYKDLSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(z)-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCO)/SSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N GFEGEDUIIYDMOX-BMJUYKDLSA-N 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- HBEJJYHFTZDAHZ-QMMMGPOBSA-N tert-butyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OC(C)(C)C HBEJJYHFTZDAHZ-QMMMGPOBSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960001385 thiamine disulfide Drugs 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011715 vitamin B12 Chemical class 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011708 vitamin B3 Chemical class 0.000 description 1
- 239000011675 vitamin B5 Chemical class 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention provides a novel anti-inflammatory agent. The anti-inflammatory agent of the present invention is selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, (D) e- (L) Hyp, and, (D) Dipeptides among Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are effective components.
Description
Technical Field
The present invention relates to a pharmaceutical or food composition containing a dipeptide.
Background
In the aging society, there is an increasing importance of measures for preventing and treating lifestyle-related diseases such as diabetes and obesity related to chronic inflammation, and circulatory diseases such as arteriosclerosis. In fact, inhibition of IL-1 β signaling or NF-. kappa.B inhibition was developed for diabetes. In chronic inflammatory diseases such as rheumatoid arthritis, a large amount of inflammatory cytokines such as TNF- α, IL-1 and IL-6 are abnormally produced and secreted, and these inflammatory cytokine suppressors are useful as excellent anti-inflammatory agents. For example, as a TNF- α inhibitor, an antibody drug such as infliximab is used as a therapeutic agent for rheumatoid arthritis (non-patent document 1). In addition, as an IL-6 inhibitor, an antibody drug tollizumab (non-patent document 2) was used. Further, protein preparations such as anakinra, elocept, and canamab, and antibody drugs have been developed as IL-1 inhibitors (non-patent document 3).
Documents of the prior art
Non-patent document
Non-patent document 1: TNF inhibitory drug guidelines for Rheumatoid Arthritis (RA) (Japan society of general law)
Non-patent document 2: pharmaceutical journal 129(6)667-674(2009)
Non-patent document 3: journal of Japan medical Association 100, volume 10, p.2985-2990(2011, 10 months and 10 days)
Disclosure of Invention
Under such circumstances, the present inventors have found that a liver hydrolysate has an excellent inhibitory effect on the production of IL-1 and is useful as a cytokine production inhibitor and an anti-inflammatory agent, and have previously made a patent application (PCT/JP 2018/006351).
However, the liver hydrolysate contains a large amount of amino acids and peptides, but the actual active ingredients have not been known.
Accordingly, an object of the present invention is to provide a novel anti-inflammatory agent based on an inhibitory effect on cytokine production.
Accordingly, the present inventors have conducted studies to develop a novel anti-inflammatory agent, and as a result, have found that a dipeptide derived from a specific D-body amino acid, not from an L-body amino acid, and that the dipeptide has an inhibitory effect on cytokine production such as IL-1 β and IL-6, by administering a liver hydrolysate to an animal, searching for indigestible peptides that are transported to the blood, and fractionating the peptides using various columns for the liver hydrolysate, and evaluating the drug efficacy.
Namely, the present invention provides the following [1] to [15 ].
[1] An anti-inflammatory agent selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, (D) e- (L) Hyp, and, (D) Dipeptides among Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are effective components.
[2] The anti-inflammatory agent according to [1], wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
[3] An inflammatory cytokine production inhibitor selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) Pro, (D) Pro- (D) Val, (D) Leu- (D) Glu, (D) Ile- (D) pGlu, (D) Val- (D) pGlu, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, (D) Dipeptides among Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are effective components.
[4] The inhibitor of inflammatory cytokine production according to [3], wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
[5] An IL-1 production inhibitor or IL-6 production inhibitor selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Dipeptides among Leu- (L) Hyp, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are active ingredients.
[6] The IL-1 production inhibitor or IL-6 production inhibitor according to [5], wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (L) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
[7] A food composition for ameliorating inflammation, which is selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, (D) Dipeptides among Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are effective components.
[8] The food composition according to [7], wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
[9] An inflammatory cytokine production-suppressing food composition comprising a peptide selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Dipeptides among Leu- (L) Hyp, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are active ingredients.
[10] The food composition according to [9], wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
[11] A food composition for inhibiting IL-1 production or a food composition for inhibiting IL-6 production, which is selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Glu, (D) Ile- (D) pGlu, (D) Val- (D) pGlu, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Pro- (L) -Pro, (D) Pro- (L) Val, Val- (L) Val, (D) Dipeptides among Leu- (L) Hyp, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are active ingredients.
[12] The food composition according to [11], wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
[13] Use of a dipeptide selected from (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, for the manufacture of an anti-inflammatory agent, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
[14] A dipeptide selected from (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) Pro, (D) Pro- (D) Val, (D) Leu- (D) Glu, (D) Ile- (D) pGlu, (D) Val- (D) pGlu, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, Val- (L) Pro, and, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
[15] A method for treating an anti-inflammatory disease, which comprises administering an effective amount of an agent selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val), (D) Dipeptides among Leu- (L) Hyp, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu, and (D) Asp- (L) Phe.
The dipeptide used in the present invention is indigestible due to its D-body amino acid origin, has an IL-1 production inhibitory activity and an IL-6 production inhibitory activity for a long period of time in blood, and is therefore useful as a drug or food composition for inhibiting cytokine production and for resisting inflammation.
Drawings
FIG. 1 shows the inhibition of IL-6 production by hydrophobic peptide fractions.
FIG. 2 shows the IL-6 production inhibition by the hydrophobic pyroglutamyl peptide fraction.
FIG. 3 shows the IL-6 production inhibition by the hydrophilic peptide fraction.
FIG. 4 shows the IL-6 production inhibition by the hydrophilic pyroglutamyl peptide fraction.
FIG. 5 shows the IL-1. beta. production inhibition by the hydrophobic peptide fraction.
FIG. 6 shows the IL-1. beta. production inhibitory effect of the hydrophobic pyroglutamyl peptide fraction.
Detailed Description
The dipeptide as the active ingredient of the anti-inflammatory agent of the present invention is selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, (D) Dipeptides of Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are preferably dipeptides selected from (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe, and more preferably (D) Asp- (D) Leu and (D) Asp- (L) Leu, from the viewpoints of transportability to the blood, duration of action and anti-inflammatory action upon oral administration.
The expression (D) means that the amino acid is in the D form. The expression (L) means that the amino acid is in the L form.
Among the α -and β -forms of the dipeptide of the above-mentioned (D) form or (L) form, the β -form is more preferable.
The dipeptide can be produced by a general liquid phase peptide synthesis method or a solid phase peptide synthesis method using the amino acid (D) as a raw material. For example, the production can be carried out by the following method: the protecting group is removed by condensing an amino acid having a functional group other than an α -amino group protected with an amino acid having a functional group other than a carboxyl group activated with an amino acid having a functional group other than a carboxyl group protected with an amino acid.
Examples of the protective group for an amino group of an amino acid include a benzyloxycarbonyl group, a tert-butoxycarbonyl group, and a fluorenylmethoxycarbonyl group. Examples of the protecting group of the carboxyl group include a tert-butyl group and a benzyl group. The condensation reaction can be carried out by a method using N, N' -dicyclohexylcarbodiimide, dicyclohexylurea or other condensing agents, an active ester method using nitrophenol, N-hydroxysuccinimide or the like, a mixed acid anhydride method or the like.
After the condensation reaction is completed, the protecting group is removed, but in the case of the solid phase method, the bond between the C-terminal of the peptide and the resin is further cleaved. Further, the peptide is purified by a usual method.
The above-mentioned dipeptides may be acid addition salts or basic salts. Examples of the acid addition salts include salts of inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, and perchloric acid; salts of organic acids such as citric acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, and trifluoroacetic acid. Examples of the basic salt include alkali metal salts such as sodium, potassium, and lithium; and salts of alkaline earth metals such as calcium and magnesium.
The peptide may be a solvate. Examples of the solvate include water (in the case of a hydrate), and solvates such as methanol, ethanol, and isopropanol.
The dipeptide has indigestibility, high blood transportability after oral administration, excellent persistence, and strong inhibitory activity against the production of IL-1. beta. and IL-6, which are one of inflammatory cytokines, and inhibitory activity against the expression of mRNA of IL-1. beta. and IL-6. Therefore, the above-mentioned dipeptide inhibits the production of inflammatory cytokines such as IL-1 and IL-6, and is useful as a therapeutic agent for inflammatory diseases associated with inflammatory cytokines and a food or beverage composition for ameliorating inflammation. Examples of diseases associated with inflammatory cytokines such as IL-1 and IL-6 include rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, sepsis, acute and chronic bone marrow leukemia, osteoporosis, and lifestyle-related diseases.
The pharmaceutical composition of the present invention can be administered by oral administration, transdermal administration, intestinal administration, intravenous administration, etc., more preferably oral administration. Examples of the preparation for oral administration include a liquid, a tablet, a powder, a fine granule, a capsule, etc., and the liquid and the tablet are preferable, and the liquid is more preferable.
To prepare these oral administration preparations, excipients such as lactose, mannitol, corn starch, crystalline cellulose, and the like; binders such as cellulose derivatives, gum arabic, and gelatin; disintegrating agents such as calcium carboxymethylcellulose; lubricants such as talc and magnesium stearate; dissolution aids such as nonionic surfactants; flavoring agent, sweetener, stabilizer, pH regulator, water, ethanol, propylene glycol, glycerol, etc. Coating agents such as hydroxymethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, and methacrylate copolymers may also be used.
In addition, other active ingredients may be incorporated into the pharmaceutical composition of the present invention. As other active ingredients, vitamin B may be mentioned1Class; thiamine, thiamine nitrate, thiamine hydrochloride, furthiamine, bisbentiamine, benfotiamine, thiamine disulfide, thiamine propyl disulfide, derivatives thereof, vitamin B2Class; riboflavinAnd derivatives and their salts, vitamin B3Class; nicotinic acid, nicotinamide and derivatives and their salts, vitamin B5Class; panthenol, pantothenic acid and derivatives, salts thereof, and vitamin B6Class; pyridoxine and derivatives and their salts, vitamin B12Class; cyanocobalamin and derivatives and their salts, other vitamins; vitamin a, vitamin C, vitamin E, vitamin K, vitamin P, diisopropylamine dichloroacetate, taurine, chondroitin sulfate, royal jelly, caffeine, turmeric, silybum marianum, dandelion, burdock, garlic, chrysanthemum, yarrow, gardenia, sesame, pseudo-ginseng, asparagus cochinchinensis, onion, chicory, common sage herb, artichoke (artichoke), medlar, a plant of leguminosae and iridaceae, zebra, shrub (Erva De Passarinho), balsam cuphea, mallotus japonicus, black tea, resveratrol, catechins, berberine, rosemary, bean extract, metformin, and the like.
In addition, the composition of the present invention can be used as a functional food such as a quasi drug, a specific health food, a sports drink, a rehabilitation drink, a pet food, and the like, in addition to a drug.
The content of the dipeptide in the pharmaceutical composition or food composition of the present invention varies depending on the form of administration, and is preferably 0.001 to 10% by mass, and more preferably 0.001 to 5% by mass. The amount of the dipeptide administered in the pharmaceutical composition or food composition of the present invention in 1 day is preferably 10mg to 1000mg, more preferably 20mg to 800mg, and still more preferably 50mg to 800 mg.
Examples
The present invention will be described in detail with reference to examples, but the present invention is not limited to these examples.
Example 1 (grading of liver hydrolysates)
(1) Fractionation of peptides and pyroglutamyl peptides
A strong cation exchange resin (AG50) was packed in Econo Column (2.5X 20cm) and the resin was equilibrated with 10mM HCl. 1g of liver hydrolysate (sample A) was dissolved in 20mL of 10mM HCl. This solution was added to the resin and 20mL of flow-through fraction (flow-through fraction 1) was recovered. Next, 20mL of 10mM HCl was added to the resin and 20mL of the flow-through fraction was recovered. This operation was repeated 19 times (flow through fractions 2 to 20). The absorbance (230nm) of the fractions 1 to 20 was measured to confirm the elution of the peptide.
Subsequently, 20mL of 50% ammonia solution was added to the resin, and 20mL of the adsorbed fraction was recovered. This operation was repeated 20 times (adsorption fractions 1 to 20). The absorbance (230nm) of the adsorbed fractions 1 to 20 was measured to confirm the elution of the peptide.
The flow-through fraction (pyroglutamyl peptide fraction) and the adsorption fraction (peptide fraction) were concentrated under reduced pressure using an evaporator.
(2) Grading of hydrophilicity and hydrophobicity
The solid phase extraction column (Sep-Pak) was equilibrated with 10mM HCl. The pyroglutamyl peptide fraction was passed through a column, and the flow-through fraction was eluted and recovered (hydrophilic pyroglutamyl peptide fraction). Subsequently, a 60% acetonitrile solution containing 10mM HCl was passed through the column, and the adsorbed fraction was eluted and recovered (hydrophobic pyroglutamyl peptide fraction).
These operations were also performed on the peptide fraction.
The 4 fractions obtained were freeze-dried.
Example 2
(1) Quantitative assay for indigestible peptides in liver hydrolysates
1) 2.5mg of liver hydrolysate was dissolved in 1mL of 50mM Tris-HCl.
2) Pancreatin (0.1mg), leucine aminopeptidase (2.45unit) and carboxypeptidase (7.7unit) were added to 1) to carry out an enzymatic reaction (37 ℃ C., 24 hours).
3) The enzyme was removed by ultrafiltration (10K).
4) Passing 3) through a strong cation exchange resin (AG50) packed in a spin column, and recovering the flow-through fraction (pyroglutamyl peptide fraction).
5) 200 μ L of 3) (peptide fraction) and 4) (pyroglutamyl peptide fraction) (SEC Fr.35-44) were fractionated by size exclusion HPLC and fractionated.
6) SEC Fr.35-44 was dried for peptide fractions and accQ was performed. SEC Fr.35-44 was used directly for the pyroglutamyl peptide fraction.
7) The structure of the indigestible peptide was determined by LC-MS/MS analysis.
Column: inertsil ODS-3
Eluent: 0.1% formic acid and 80% acetonitrile containing 0.1% formic acid
The analysis method comprises the following steps: after a fragment (m/z 171.1) of AccQ was specifically detected (precarsor ion scan analysis) in the peptide fraction, the structure was estimated by MS/MS analysis, and a standard was synthesized, and identified and quantified by MRM analysis.
After a peak was detected by Total scan analysis for the pyroglutamyl peptide fraction, a structure was estimated by MS/MS analysis, and a standard product was synthesized and identified and quantified by MRM.
(2) Experiment of peptide transport in blood when liver hydrolysate was administered to rat
1) A single dose of aqueous liver hydrolysate (10g/60kg) was administered to Uster rats (6 weeks old, male).
2) After 30 and 60 minutes of administration, blood was collected from the abdominal vena cava under isoflurane anesthesia to obtain plasma. The digestive tract (duodenum-ileum) was then removed, and the contents of the lumen were dissolved in 10mL of physiological saline. To the plasma and gut contents was added 3-fold amount of ethanol (stored at-20 ℃ C. prior to analysis).
3) The ethanol supernatant of the plasma and the contents of the digestive tract were dried and AccQ-treated.
4) Identification and quantification of the indigestible peptide identified in (1) by MRM analysis.
The dipeptide concentration in blood is shown in Table 1.
[ Table 1]
(pmolmL)
| (min) | Asp-Leu(Dα) | Asp-Val(Dα) | Asp-Ile(Dα) | Asp-Phe(Dα) |
| 0 | 2.03±0.94 | ND | 2.03±0.94 | 0.09±0.16 |
| 60 | 16.43±2.09** | 8.84±0.85** | 16.43±2.10** | 2.08±0.09** |
| (min) | Asp-Leu(Dβ) | Asp-Val(Dβ) | Asp-Ile(Dβ) | Asp-Phe(Dβ) |
| 0 | 3.41±0.50 | ND | 3.56±1.28 | 1.54±0.62 |
| 60 | 28.54±2.83** | 16.31±3.27* | 26.37±2.66** | 17.67±3.25** |
Average (n ═ 3) ± SD ≦ 0.05, and ≦ 0.01
Asp-Leu (D α), Asp-Val (D α): Asp-Leu cannot be separated in LC, and therefore,
are all Asp-Ile + Asp-Leu (D alpha)
As a result, it was found that (D) Asp- (D) Val, (D) Asp- (D) Phe, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu, and (D) Asp- (L) Phe had good blood transportability by oral administration and continued for a long period of time in the blood.
Example 3 (Synthesis of dipeptide)
1) The reagents were added to an eggplant type flask in the following order, and the reaction was carried out while stirring (4 ℃ C., overnight).
(i)H-Leu-OtBu·HCl
(ii)DMF
(iii)TEA
(iv) Boc-Asp (OtBu) -OH (L.alpha.body)
(v)HOBt
(vi)EDL·HCl
In the case of the other isomers, the following protected amino acids were used.
Boc-D-Asp (OtBu) -OH (D.alpha.body)
Boc-Asp-OtBu (L beta body)
Boc-D-Asp-OtBu (D β form)
2) DMF was removed using an evaporator.
3) Dissolved in ethyl acetate and transferred to a separatory funnel.
4) 5% sodium bicarbonate was added and stirred, and the aqueous layer was removed. (. times.2)
5) 10% citric acid was added and stirred, and the aqueous layer was removed. (. times.2)
6) Saturated brine was added and stirred, and the aqueous layer was removed.
7) The ethyl acetate layer was recovered, and sodium hydrogensulfate was added to dehydrate the ethyl acetate layer.
8) The ethyl acetate layer was recovered by filtration and concentrated by an evaporator.
9) Petroleum ether was added and the resulting precipitate was dried. (proceed to 10 without precipitation)
10) Adding 4M HCl/bis to the dry product
Alkane is reacted while stirring (at 4 ℃, 24-48 h).
11) 4M HCl/bis using an evaporator
And (4) removing the alkane.
12) Diethyl ether was added, the resulting precipitate was broken and washed with ultrasound, and the ether supernatant was removed with decane. (. times.3)
13) Ether was added and left to stand (4 ℃, overnight).
14) Diethyl ether was added, the resulting precipitate was broken and washed with ultrasound, and the ether supernatant was removed with decane. (. times.3)
15) The precipitate was dried.
Example 4
The number of cells in RAW264.7 cells was adjusted to 1.5X 106cells/dish were inoculated and cultured evening-out. The pre-fractionated sample or filtrate fractions were diluted 20-fold together in EMEM medium (final concentration about 0.6 mg/mL). As a control, PBS was diluted 20-fold in EMEM medium instead of samples. Each of the samples (control, pre-fractionation, filtrate fraction) diluted in the culture medium was added to each dish group. After 24 hours of incubation, Lipopolysaccharide (LPS) was added so that the final concentration became 1.0. mu.g/mL. Standing for 3 hoursRNA was recovered and cDNA synthesis was performed by reverse transcription. Then, EEF1A1 and IL-6 were measured by RT-RCR.
The results are shown in FIGS. 1 to 4.
In the RAW cells stimulated with LPS, the mRNA expression levels of the inflammation-related genes were compared between the dipeptide group and the control group to which PBS was added instead of the dipeptide, and as a result, IL-6 was significantly reduced in the hydrophobic peptide fraction and the hydrophobic pyroglutamyl peptide fraction, indicating the inflammation inhibitory effect of the dipeptide.
Example 5
The number of cells in RAW264.7 cells was adjusted to 1.5X 106cells/dish were inoculated and cultured evening-out. The pre-fractionated sample or filtrate fractions were diluted 20-fold together in EMEM medium (final concentration about 0.6 mg/mL). As a control, PBS was diluted 20-fold in EMEM medium instead of samples. Each of the samples (control, pre-fractionation, filtrate fraction) diluted in the culture medium was added to each dish group. After 24 hours of incubation, Lipopolysaccharide (LPS) was added so that the final concentration became 1.0. mu.g/mL. After standing for 3 hours, RNA was recovered and cDNA synthesis was performed by reverse transcription. Then, EEF1A1 and IL-1. beta. were measured by RT-RCR.
The results are shown in fig. 5 to 6.
In the RAW cells stimulated with LPS, the mRNA expression levels of inflammation-related genes were compared between the dipeptide group and the control group to which PBS was added instead of the dipeptide, and as a result, IL-1 β was significantly reduced in the hydrophobic peptide fraction, indicating the inflammation inhibitory effect of the dipeptide.
Claims (15)
1. An anti-inflammatory agent selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, (D) Dipeptides among Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are effective components.
2. An anti-inflammatory agent according to claim 1, wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
3. An inflammatory cytokine production inhibitor selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, (D) Dipeptides among Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are effective components.
4. The inflammatory cytokine production inhibitor according to claim 3, wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
5. An IL-1 production inhibitor or IL-6 production inhibitor selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Dipeptides among Leu- (L) Hyp, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are active ingredients.
6. The IL-1 production inhibitor or IL-6 production inhibitor according to claim 5, wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
7. A food composition for ameliorating inflammation, which is selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, (D) Dipeptides among Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are effective components.
8. The food composition according to claim 7, wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
9. An inflammatory cytokine production-suppressing food composition comprising a peptide selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Dipeptides among Leu- (L) Hyp, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are active ingredients.
10. The food composition according to claim 9, wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
11. A food composition for inhibiting IL-1 production or a food composition for inhibiting IL-6 production, which is selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Glu, (D) Ile- (D) pGlu, (D) Val- (D) pGlu, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Pro- (L) -Pro, (D) Pro- (L) Val, Val- (L) Val, (D) Dipeptides among Leu- (L) Hyp, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe are active ingredients.
12. The food composition according to claim 11, wherein the active ingredient is selected from the group consisting of (D) Asp- (D) Val, (D) Asp- (D) Ile, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Asp- (L) Val, (D) Asp- (L) Ile, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
13. Use of a dipeptide selected from (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, for the manufacture of an anti-inflammatory agent, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
14. A dipeptide selected from (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) Pro, (D) Pro- (D) Val, (D) Leu- (D) Glu, (D) Ile- (D) pGlu, (D) Val- (D) pGlu, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val, (D) Leu- (L) Hyp, Val- (L) Pro, and, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu and (D) Asp- (L) Phe.
15. A method for treating an anti-inflammatory disease, which comprises administering an effective amount of an agent selected from the group consisting of (D) Ile- (D) Pro, (D) Leu- (D) Pro, (D) Pro- (D) Ile, (D) Pro- (D) Leu, (D) Val- (D) -Pro, (D) Pro- (D) Val, (D) Leu- (D) Hyp, (D) Ile- (D) Hyp, (D) Val- (D) Hyp, (D) Asp- (D) Ile, (D) Asp- (D) Val, (D) Asp- (D) Leu, (D) Asp- (D) Phe, (D) Ile- (L) Pro, (D) Leu- (L) Pro, (D) Pro- (L) Ile, (D) Pro- (L) Leu, (D) Val- (L) -Pro, (D) Pro- (L) Val), (D) Dipeptides among Leu- (L) Hyp, (D) Ile- (L) Hyp, (D) Val- (L) Hyp, (D) Asp- (L) Ile, (D) Asp- (L) Val, (D) Asp- (L) Leu, and (D) Asp- (L) Phe.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018084926 | 2018-04-26 | ||
| JP2018-084926 | 2018-04-26 | ||
| PCT/JP2019/017657 WO2019208701A1 (en) | 2018-04-26 | 2019-04-25 | Pharmaceutical composition containing dipeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112020366A true CN112020366A (en) | 2020-12-01 |
Family
ID=68295494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980028106.3A Pending CN112020366A (en) | 2018-04-26 | 2019-04-25 | Pharmaceutical composition containing dipeptide |
Country Status (6)
| Country | Link |
|---|---|
| JP (2) | JPWO2019208701A1 (en) |
| KR (1) | KR20210003753A (en) |
| CN (1) | CN112020366A (en) |
| SG (1) | SG11202010046WA (en) |
| TW (1) | TWI822770B (en) |
| WO (1) | WO2019208701A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102224161A (en) * | 2008-09-22 | 2011-10-19 | 日清药业股份有限公司 | Antiinflammatory peptide |
| WO2016190395A1 (en) * | 2015-05-27 | 2016-12-01 | キリン株式会社 | Inflammation-suppressing composition including peptide |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6126939A (en) * | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| WO2018155525A1 (en) * | 2017-02-23 | 2018-08-30 | ゼリア新薬工業株式会社 | Anti-inflammatory agent |
-
2019
- 2019-04-25 JP JP2020515566A patent/JPWO2019208701A1/en active Pending
- 2019-04-25 CN CN201980028106.3A patent/CN112020366A/en active Pending
- 2019-04-25 SG SG11202010046WA patent/SG11202010046WA/en unknown
- 2019-04-25 KR KR1020207030149A patent/KR20210003753A/en unknown
- 2019-04-25 WO PCT/JP2019/017657 patent/WO2019208701A1/en active Application Filing
- 2019-04-26 TW TW108114725A patent/TWI822770B/en active
-
2023
- 2023-11-14 JP JP2023193372A patent/JP2024003144A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102224161A (en) * | 2008-09-22 | 2011-10-19 | 日清药业股份有限公司 | Antiinflammatory peptide |
| WO2016190395A1 (en) * | 2015-05-27 | 2016-12-01 | キリン株式会社 | Inflammation-suppressing composition including peptide |
Non-Patent Citations (2)
| Title |
|---|
| SHERI M. FUJIHARA等: "A D-Amino Acid Peptide Inhibitor of NF-κB Nuclear Localization Is Eycacious in Models of In|ammatory Disease", THE JOURNAL OF IMMUNOLOGY * |
| 汪雄;赵燕;徐明生;姚瑶;张梦雅;涂勇刚;: "食源性抗炎肽的制备、分离、鉴定及其抗炎机制研究进展", 食品工业科技 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019208701A1 (en) | 2019-10-31 |
| TWI822770B (en) | 2023-11-21 |
| TW202014197A (en) | 2020-04-16 |
| JPWO2019208701A1 (en) | 2021-05-13 |
| JP2024003144A (en) | 2024-01-11 |
| KR20210003753A (en) | 2021-01-12 |
| SG11202010046WA (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100827973B1 (en) | Novel peptides | |
| JP4699374B2 (en) | Stable peptide and polypeptide analog therapeutic agents | |
| JP5176964B2 (en) | Dipeptidyl peptidase IV inhibitor | |
| CN107001439A (en) | GIP agonist compounds and method | |
| EP2380901A1 (en) | Angiotensin converting enzyme inhibitory peptide | |
| CN101282657A (en) | Methods for the use of branched chain amino acids | |
| EP1930017B1 (en) | Composition effective for prevention and treatment of adult disease | |
| JP2805194B2 (en) | Peptide for increasing blood triglyceride concentration and blood triglyceride concentration increase inhibitor containing the peptide as an active ingredient | |
| KR101887576B1 (en) | Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof | |
| KR20110093899A (en) | Tumor necrosis factor alpha inhibiting peptides and uses thereof | |
| JP2023089192A (en) | Dipeptide and pharmaceutical composition comprising the same | |
| WO2014002571A1 (en) | Angiotensin-converting-enzyme inhibiting dipeptide | |
| JP2000507925A (en) | Synthetic and pseudopeptides having osteogenic activity and pharmaceutical preparations containing them | |
| CN112020366A (en) | Pharmaceutical composition containing dipeptide | |
| KR102288716B1 (en) | Peptide for anti-obesity and use thereof | |
| CN110198723B (en) | Anti-inflammatory agent | |
| JP2014005243A (en) | Dipeptide inhibitor of angiotensin-converting enzyme | |
| KR101920047B1 (en) | Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof | |
| CN117717601A (en) | Application of polypeptide in preparation of medicine for treating or preventing non-alcoholic fatty liver disease | |
| KR100594989B1 (en) | Compound for improving hypertension containing inhibitors of angiotensin converting enzyme activity extracted from marin plants and articles comprising thereof | |
| CN117120462A (en) | Use of polypeptide compounds for preventing or treating inflammatory bowel disease and related intestinal fibrosis | |
| CN113874029A (en) | CP 2C-targeting peptide-based anticancer agents | |
| WO2008050161A2 (en) | Peptides for activation of angiogenesis, pharmaceutical compounds containing same and use of these compounds | |
| JP2002138097A (en) | Novel peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |